SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640455-22-000089
Filing Date
2022-08-04
Accepted
2022-08-04 12:36:19
Documents
59
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q jnce-20220630.htm   iXBRL 10-Q 1133459
2 EX-10.1 jnce06302022exhibit101.htm EX-10.1 15847
3 EX-31.1 jnce06302022exhibit311.htm EX-31.1 9183
4 EX-31.2 jnce06302022exhibit312.htm EX-31.2 9191
5 EX-32.1 jnce06302022exhibit321.htm EX-32.1 7506
  Complete submission text file 0001640455-22-000089.txt   5152162

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20220630.xsd EX-101.SCH 29557
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20220630_cal.xml EX-101.CAL 47021
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20220630_def.xml EX-101.DEF 146814
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20220630_lab.xml EX-101.LAB 440899
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20220630_pre.xml EX-101.PRE 280149
53 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20220630_htm.xml XML 875896
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37998 | Film No.: 221135649
SIC: 2836 Biological Products, (No Diagnostic Substances)